Recruiting Neuroendocrine Tumors Studies in Miami
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected s...
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors
This study is Phase I/IIa First-in-Human Study of \[212Pb\]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors...
Study to Determine the Pharmacokinetics and Pharmacodynamic Effects of Phenylephrine on BP Via IV
The primary objective of this study is to evaluate the dose effect of Phenylephrine Hydrochloride Injection on the treatment of clinically relevant decreased blood pressure in the pediatric population...
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
This phase II trial compares the effect of retreatment with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) to the usual approach of treatment with everolimus, sunitinib, or cabozantinib i...
Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors
This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients ...
CapTemY90 for Grade 2/3 NET Liver Metastases
This is a Phase 2 evaluation of hepatic-progression free survival among patients with Grade 2 liver-dominant NET metastases undergoing combination therapy with CapTem and Y90 radioembolization.The hyp...
About Neuroendocrine Tumors Clinical Trials in Miami
Neuroendocrine tumors (NETs) develop from hormone-producing cells and can occur in many organs, most commonly the gastrointestinal tract and lungs. They range from slow-growing to aggressive. Treatment includes surgery, somatostatin analogs, targeted therapy, and peptide receptor radionuclide therapy.
There are currently 6 neuroendocrine tumors clinical trials recruiting participants in Miami, FL. These studies are seeking a combined 912 participants. Research is being sponsored by RayzeBio, Inc., Perspective Therapeutics, West-Ward Pharmaceutical and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Neuroendocrine Tumors Clinical Trials in Miami — FAQ
Are there neuroendocrine tumors clinical trials in Miami?
Yes, there are 6 neuroendocrine tumors clinical trials currently recruiting in Miami, FL. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Miami?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Miami research site will contact you about next steps.
Are clinical trials in Miami free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Miami studies also compensate for your time and travel.
What neuroendocrine tumors treatments are being tested?
The 6 active trials in Miami are testing new therapies including novel drugs, biologics, and treatment approaches for neuroendocrine tumors.
Data updated March 2, 2026 from ClinicalTrials.gov